Out in @TheLancetHaem, our Correspondence on AMLSG 09–09 by Döhner et al.
1/🚩The AMLSG09-09 study added gemtuzumab ozagamicin (GO) to chemo in patients w/ NPM1-mutated AML. Despite no ΔOS/EFS, authors conclude young patients benefit due to lower relapse rates. We're skeptical🤔
The attitude that we should just “move on” and accept poorly designed trial results is a major problem in oncology.
We need to demand better designed trials, w/ appropriate SOC control arms and endpoints that matter.
Trials should be designed for patients, not for profits.
As therapeutic options for #MF expand, a timely consensus paper from an expert panel on the highly nuanced subject of ruxolitinib “failure” or suboptimal response & their management.
@bose_prithviraj@MDAndersonNews#Leukemia
https://t.co/v9WKt7twwB
@Berninini Honestly it’s been crazy with the amount of “practice changing” data coming out that’s validated only in single center populations. I think there are some great regimens being assessed but should not abandon phase 3 data entirely :(
@OtterPharm I’m a once per day but at night prior to bed. I’d rather full shower post working/working out and sleep in clean sheets and do a hair wash/style in the morning.
Excellent analysis of the some of the issues in this trial by @AaronGoodman33 and colleagues Ivosidenib and Azacitidine in IDH1-Mutated AML | NEJM https://t.co/szCFrxJsSw
@shhhhtokyo @AmbCareRx Still potentially one of the most challenging experiences and really taught me “it’s just three to four times a day” is a daunting task to remember even for someone who was “somewhat” medically literate…
BREAKING: ASH President @JaneWinterMD advocates for the right to maternal health care in response to this morning’s #SCOTUS decision. Read more: https://t.co/me5hJW71RX
Jason definitely struck a nerve for many of the #PharmEd & #TwitteRx folks. This is something we’ve discussed quite a bit in Maryland, but it sounds like a larger @ASHPOfficial / @ACCP task force is needed. A few thoughts… (🧵1/10)